Viral Hepatitis is caused by a group of viruses that affects human liver and subsequently damages it to the extent where it stops functioning.   Leading factors contributing to the rise in Hepatitis are unscreened blood transfusions, usage of unsterilized instruments in surgeries and dental procedures and reuse of needles for injections.  Unfortunately a vast majority of these patients go undiagnosed till a very late stage on account of lack of awareness & education, silent nature of disease. (

Please note that Roche is unable to answer questions on individual disease treatment / management matters. These should be discussed with your doctor. As product information and availability varies from country to country, we are able to respond to Pakistan enquiries only. We cannot answer product-related questions through this website.

Following products are currently marketed by Roche Pakistan. The below information is a guide only.


Ropegra (Peginterferon alfa-2a)



Ropegra (Peginterferon alfa-2a)


Chronic Hepatitis B:

Ropegra is indicated for the treatment of both HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) in non-cirrhotic and cirrhotic patients with compensated liver disease and evidence of viral replication and liver inflammation.

Chronic Hepatitis C:

Ropegra is indicated in combination with other medicinal products, or alone for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease. This includes patients with or without liver cirrhosis, treatment-naive patients, patients who have failed previous treatment and patients co-infected with clinically stable HIV.

Roche Pakistan Limited is pleased to inform you that Roche’s Pegylated Interferon alfa-2a 180 mcg (40KD) is now available in Pakistan under the brand name of ROPEGRA.

F. Hoffmann-La Roche Ltd, Basel Switzerland, confirms that ROPEGRA (Pegylated Interferon alfa-2a) 180 mcg (40KD)drug product is identical to and same as in comparison with PEGASYS (Pegylated Interferon  alfa-2a) 180 mcg (40KD). 

No Change has been made in the composition, manufacturing process and manufacturing sites, overall quality, analytical procedures, specifications and active or inactive ingredients. The only difference is the Trade Name or the Brand Name.

ROPEGRA is manufactured in Basel, Switzerland and is approved by European Medicines Agency (EMA) for Pakistan.

ROPEGRA is available since March 2014 in Pakistan.

If you have any queries with reference to ROPEGRA, please do not hesitate to contact Roche Pakistan Limited.